Bacterial Vaginosis (BV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Bacterial Vaginosis (BV) Marketed and Pipeline Drugs Report Overview
Bacterial Vaginosis is the most commonly occurring vaginal infection in women of reproductive age. It occurs when the healthy vaginal flora is dominated by BV-associated bacteria (BVAB). The most common BVAB includes Gardnerella vaginalis, Atopobium vaginae, Megasphaera spp., Prevotella spp., and Sneathia spp. BVAB is caused by almost 35 unique bacterial species: a few of them are less frequently detected, including species such as Peptostreptococcus spp., Aerococcus, Anaerococcus, Gemella, and Veillonella genera.
Key Mechanism of Action (Marketed) | · Gene, Nucleic Acid, and Related Component Inhibitors
· Cells and Cell Organelle Inhibitor · Protein and Peptide Inhibitor · Enzyme Inhibitor |
Key Routes of Administration (Marketed) | · Oral
· Injection · Topical · Inhalational · Suppository |
Key Molecule Type (Marketed) | · Small Molecule
· Polymer |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Bacterial Vaginosis marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Bacterial Vaginosis.
The report also provides actionable insights on the clinical and commercial landscapes of Bacterial Vaginosis drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
Key Mechanisms of Action (Pipeline) | · Cells and Cell Organelle Inhibitor
· Enzyme Inhibitor · Gene, Nucleic Acid, and Related Component Inhibitors |
Key Routes of Administration (Pipeline) | · Suppository
· Injection · Oral · Topical |
Key Molecule Types (Pipeline) | · Biologics
· Small Molecules |
Top Sponsors (Marketed and Pipeline Drugs) | · TenNor Therapeutics Ltd
· Ahvaz Jundishapur University of Medical Sciences · Lupin Ltd · Mashhad University of Medical Sciences · AVVA Rus |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Bacterial Vaginosis Marketed Drugs Segmentation by Mechanisms of Action
The key MoA in the marketed drugs for Bacterial Vaginosis are gene, nucleic acid, and related component inhibitors, cells and cell organelle inhibitor, protein and peptide inhibitor, and enzyme inhibitor. The majority of the marketed drugs used for BV were gene, nucleic acid, and related component inhibitors, followed by cell and cell organelle inhibitors in 2023.
Bacterial Vaginosis Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Bacterial Vaginosis Marketed Drugs
Bacterial Vaginosis Marketed Drugs Segmentation by Routes of Administration
Most of the Bacterial Vaginosis marketed drugs are orally administered. It is followed by injectable, topical, inhalational, and suppository.
Bacterial Vaginosis Marketed Drugs Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Bacterial Vaginosis Marketed Drugs
Bacterial Vaginosis Marketed Drugs Segmentation by Molecule Types
Key molecule types in the marketed drugs for Bacterial Vaginosis are small molecule and polymer. The majority of innovator-marketed drugs for BV were small molecules in 2023.
Bacterial Vaginosis Marketed Drugs Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Bacterial Vaginosis Marketed Drugs
Bacterial Vaginosis Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA in the pipeline drugs for Bacterial Vaginosis are cells and cell organelle inhibitor, enzyme inhibitor, and gene, nucleic acid, and related component inhibitors. In 2023, all these MoAs had an equal number of products in the pipeline in the Bacterial Vaginosis drugs market.
Bacterial Vaginosis Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy Full Report to Know More about the MoA of Bacterial Vaginosis Pipeline Drugs
Bacterial Vaginosis Pipeline Drugs Market Segmentation by Routes of Administration
Most pipeline drugs for Bacterial Vaginosis followed suppository RoA in 2023. The other popular routes of administration for BV are oral, topical, and injection.
Bacterial Vaginosis Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy Full Report to Know More about the RoA of Bacterial Vaginosis Pipeline Drugs
Bacterial Vaginosis Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in Bacterial Vaginosis pipeline drugs market are biologics and small molecules. In 2023, the pipeline of drugs for BV was dominated by biologics molecule type.
Bacterial Vaginosis Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Bacterial Vaginosis Pipeline Drugs
Bacterial Vaginosis Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the Bacterial Vaginosis marketed and pipeline drugs market are TenNor Therapeutics Ltd, Ahvaz Jundishapur University of Medical Sciences, Lupin Ltd, Mashhad University of Medical Sciences, and AVVA Rus. In 2023, TenNor Therapeutics conducted the highest number of completed trials, followed by academic sponsors such as Ahvaz Jundishapur University of Medical Sciences.
Bacterial Vaginosis Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy Full Report for More Sponsor Insights into the Bacterial Vaginosis Marketed and Pipeline Drugs Market
Segments Covered in the Report
Bacterial Vaginosis Marketed Drugs Mechanism of Action (Number of Drugs, 2023)
- Gene, Nucleic Acid, and Related Component Inhibitors
- Cells and Cell Organelle Inhibitor
- Protein and Peptide Inhibitor
- Enzyme Inhibitors
Bacterial Vaginosis Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Topical
- Inhalational
- Suppository
Bacterial Vaginosis Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Cells and Cell Organelle Inhibitor
- Enzyme Inhibitor
- Gene, Nucleic Acid, and Related Component Inhibitors
Bacterial Vaginosis Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Suppository
- Injection
- Oral
- Topical
Bacterial Vaginosis Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small Molecules
Scope
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Bacterial Vaginosis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Bacterial Vaginosis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which was the leading MoA for Bacterial Vaginosis marketed drugs in 2023?
The majority of marketed drugs used for BV were gene, nucleic acid, and related component inhibitors, followed by cell and cell organelle inhibitors in 2023.
-
Which was the leading RoA for Bacterial Vaginosis marketed drugs in 2023?
In 2023, most of the marketed drugs for Bacterial Vaginosis were administered orally.
-
Which was the leading MoA for Bacterial Vaginosis pipeline drugs in 2023?
In 2023, cells and cell organelle inhibitor, enzyme inhibitor, and gene, nucleic acid, and related component inhibitors had an equal number of products in the pipeline in the Bacterial Vaginosis drugs market.
-
Which was the leading RoA for Bacterial Vaginosis pipeline drugs in 2023?
Most pipeline drugs for Bacterial Vaginosis followed suppository RoA in 2023.
-
Which was the leading molecule type for Bacterial Vaginosis pipeline drugs in 2023?
In 2023, the pipeline of drugs for BV was dominated by biologics molecule type.
-
Who are the top sponsors for the Bacterial Vaginosis marketed and pipeline drugs market?
A few of the top sponsors in the Bacterial Vaginosis marketed and pipeline drugs market are TenNor Therapeutics Ltd, Ahvaz Jundishapur University of Medical Sciences, Lupin Ltd, Mashhad University of Medical Sciences, and AVVA Rus.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.